During the past decade, Hämophilie-Zentrum Rhein Main GmbH conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 9 clinical trials were completed, i.e. on average, 56.3% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 4 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hämophilie-Zentrum Rhein Main GmbH" #1 sponsor was "Shire" with 8 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "CSL Behring" with 2 trials sponsored, "CENTOGENE GmbH Rostock" with 1 trials sponsored and "Emory University" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hämophilie-Zentrum Rhein Main GmbH" #1 collaborator was "Takeda Development Center Americas, Inc." with 2 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Dyax Corp." with 1 trials as a collaborator, "Lund University Hospital" with 1 trials as a collaborator and "Octapharma" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Hämophilie-Zentrum Rhein Main GmbH" are "Hereditary Angioedema (HAE)" (8 trials), "Hemophilia A" (5 trials), "Hereditary Angioedema" (4 trials), "Factor IX Deficiency" (1 trials) and "Factor VIII Deficiency" (1 trials). Many other conditions were trialed in "Hämophilie-Zentrum Rhein Main GmbH" in a lesser frequency.

Most popular intervention types in "Hämophilie-Zentrum Rhein Main GmbH" are "Drug" (11 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Emicizumab" (4 trials), "Placebo" (4 trials), "Activated prothrombin complex concentrate (aPCC)" (1 trials), "C1 esterase inhibitor [human] liquid" (1 trials) and "CINRYZE 1000" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hämophilie-Zentrum Rhein Main GmbH" are 18 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hämophilie-Zentrum Rhein Main GmbH". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Hämophilie-Zentrum Rhein Main GmbH, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hämophilie-Zentrum Rhein Main GmbH, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".